Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Andrew Callos Sells 2,886 Shares

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Andrew Callos sold 2,886 shares of the business’s stock in a transaction on Monday, April 7th. The shares were sold at an average price of $35.78, for a total transaction of $103,261.08. Following the sale, the executive vice president now directly owns 64,689 shares in the company, valued at $2,314,572.42. The trade was a 4.27 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Andrew Callos also recently made the following trade(s):

• On Monday, March 17th, Andrew Callos sold 2,775 shares of Cytokinetics stock. The shares were sold at an average price of $44.38, for a total value of $123,154.50.
• On Friday, March 14th, Andrew Callos sold 100 shares of Cytokinetics stock. The stock was sold at an average price of $45.00, for a total value of $4,500.00.
• On Thursday, March 6th, Andrew Callos sold 3,341 shares of Cytokinetics stock. The shares were sold at an average price of $43.27, for a total value of $144,565.07.

Cytokinetics Trading Up 1.4 %

CYTK stock opened at $37.85 on Friday. Cytokinetics, Incorporated has a one year low of $32.74 and a one year high of $75.50. The company has a market capitalization of $4.48 billion, a PE ratio of -7.04 and a beta of 0.94. The company’s 50 day moving average price is $43.38 and its two-hundred day moving average price is $48.28. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) EPS for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.03. The business had revenue of $16.93 million during the quarter, compared to analysts’ expectations of $14.26 million. As a group, analysts predict that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on CYTK. Stifel Nicolaus assumed coverage on shares of Cytokinetics in a research report on Wednesday, January 22nd. They issued a “buy” rating and a $80.00 price objective for the company. Royal Bank of Canada raised their price target on shares of Cytokinetics from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Wednesday, December 18th. Morgan Stanley set a $67.00 price target on shares of Cytokinetics in a report on Friday, March 7th. Citigroup began coverage on Cytokinetics in a research note on Friday, February 7th. They set a “buy” rating and a $86.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $120.00 target price on shares of Cytokinetics in a research note on Friday, April 4th. Two research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $82.00.

Institutional Investors Weigh In On Cytokinetics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Harvey Capital Management Inc. purchased a new position in Cytokinetics in the 4th quarter worth approximately $1,040,000. abrdn plc boosted its stake in shares of Cytokinetics by 29.4% during the fourth quarter. abrdn plc now owns 450,513 shares of the biopharmaceutical company’s stock valued at $21,192,000 after purchasing an additional 102,457 shares during the period. AlphaQuest LLC grew its holdings in shares of Cytokinetics by 113,500.0% in the fourth quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 1,135 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Cytokinetics by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 11,915,821 shares of the biopharmaceutical company’s stock worth $560,520,000 after buying an additional 154,216 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Cytokinetics by 1.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,335,189 shares of the biopharmaceutical company’s stock valued at $62,807,000 after buying an additional 13,798 shares during the last quarter.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.